Clinical Trial Update: A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing 177Lu-PSMA617 theranostic therapy to cabazitaxel in progressive metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA617 (177Lu-PSMA617)
• Cabazitaxel (cabazitaxel)

Snippet

Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Conditions: Cancer of the Prostate, Metastatic Cancer | Phase 2 | Status: COMPLETED